Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | Director | March 05, 2021 | March 09, 2021 |
| Mirati Therapeutics, Inc.MRTX · Entity 94908 | Director | January 15, 2021 | January 20, 2021 |
| Mirum Pharmaceuticals, Inc.MIRM · Entity 2416 | Director | June 15, 2026 | June 18, 2026 |
| OnKure Therapeutics, Inc.OKUR · Entity 6550 | Director | August 07, 2026 | August 11, 2026 |
| SPRUCE BIOSCIENCES, INC.SPRB · Entity 6471 | Director · Executive Chairman | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date March 05, 2021 · Filed March 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,840 |
Ending reported balance
After 2021-03-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-03-05 · Exercise / conversion · Acquired 5,000 · Balance 47,840 Row 2 · 2021-03-05 · Sale · Disposed 5,000 · Balance 42,840 |
| Stock Option (Right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $26.49 · Expires 2021-05-11 | Direct | 0 |
Reported balance
After 2021-03-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-03-05 · Exercise / conversion · Disposed 5,000 · Balance 0 F1: Reflects the number of options outstanding after the transactions from this specific stock option grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the number of options outstanding after the transactions from this specific stock option grant.
Mirati Therapeutics, Inc.
Report date January 15, 2021 · Filed January 20, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,731 |
Reported balance
After 2021-01-15 transaction · row 1
1 source rowRow 1 · 2021-01-15 · Grant · Acquired 1,475 · Balance 5,731 F1: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. |
| Non Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $214.47 · Expires 2031-01-14 | Direct | 2,155 |
Reported balance
After 2021-01-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-15 · Grant · Acquired 2,155 · Balance 2,155 F2: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date.
F2: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant.
Mirum Pharmaceuticals, Inc.
Report date June 15, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $101.00 · Expires 2036-06-14 | Direct | 3,772 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 3,772 · Balance 3,772 F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,980 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Grant · Acquired 1,980 · Balance 1,980 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
OnKure Therapeutics, Inc.
Report date August 07, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2036-08-06 | Direct | 22,350 |
Reported balance
After 2026-08-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-07 · Grant · Acquired 22,350 · Balance 22,350 F1: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.
SPRUCE BIOSCIENCES, INC.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.70 · Expires 2036-05-20 | Direct | 1,700 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 1,700 · Balance 1,700 F1: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Horizon Therapeutics Public Ltd Co
Report date October 06, 2023 · Filed October 06, 2023
Section 16 reporting ended · disclosed 2023-10-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 1
1 source rowRow 1 · 2023-10-06 · Disposition to issuer · Disposed 39,361 · Balance 0 F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Davy Trust | 0 |
Reported balance
After 2023-10-06 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-10-06 · Disposition to issuer · Disposed 48,031 · Balance 0 F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Family Trust | 0 |
Reported balance
After 2023-10-06 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2023-10-06 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.53 · Expires 2025-05-05 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-10-06 · Disposition to issuer · Disposed 8,548 · Balance 0 F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2: The Option (as defined in footnote 3 to this Form 4) is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.23 · Expires 2026-05-02 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-10-06 · Disposition to issuer · Disposed 23,092 · Balance 0 F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2: The Option (as defined in footnote 3 to this Form 4) is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.12 · Expires 2027-05-02 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-10-06 · Disposition to issuer · Disposed 31,153 · Balance 0 F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2: The Option (as defined in footnote 3 to this Form 4) is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.87 · Expires 2028-05-02 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-10-06 · Disposition to issuer · Disposed 32,161 · Balance 0 F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2: The Option (as defined in footnote 3 to this Form 4) is fully vested. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2024-07-27 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-10-06 · Disposition to issuer · Disposed 4,016 · Balance 0 F4: Each RSU (as defined in footnote 6 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F6: Reflects the disposition of Issuer's restricted stock unit awards (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration. F5: The Ordinary Shares subject to the RSUs vest on July 27, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").
F2: The Option (as defined in footnote 3 to this Form 4) is fully vested.
F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option.
F4: Each RSU (as defined in footnote 6 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer.
F5: The Ordinary Shares subject to the RSUs vest on July 27, 2024.
F6: Reflects the disposition of Issuer's restricted stock unit awards (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2026 Filed Aug 11, 2026 20:36 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantStock Option (right to buy) · Derivative | 22,350 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001240122-26-000006 · form4-08112026_080811.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,350 Underlying: Class A Common Stock · 22,350 shares Expires 2036-08-06 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. Read SEC document |
| June 15, 2026 Filed Jun 18, 2026 00:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantRestricted Stock Units · Derivative | 1,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001240122-26-000005 · form4-06172026_080601.xml · derivative · entry 2 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,980 Underlying: Common Stock · 1,980 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Read SEC document |
| June 15, 2026 Filed Jun 18, 2026 00:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 3,772 | $0.00 Strike: $101.00 | $0.00 |
DisclosureSEC source: 0001240122-26-000005 · form4-06172026_080601.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,772 Underlying: Common Stock · 3,772 shares Expires 2036-06-14 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 22:24 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantStock Option (right to buy) · Derivative | 7,650 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001240122-26-000003 · form4-06082026_100628.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,650 Underlying: Class A Common Stock · 7,650 shares Expires 2036-06-03 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:30 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 1,700 | $0.00 Strike: $52.70 | $0.00 |
DisclosureSEC source: 0001240122-26-000002 · form4-05262026_040505.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,700 Underlying: Common Stock · 1,700 shares Expires 2036-05-20 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 23:50 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001240122-25-000011 · form4-12232025_111200.xml · derivative · entry 5 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,176 Underlying: Common Stock · 50,000 shares Expires 2029-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 23:50 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 50,000 | $78.00 | $3,900,000.00 |
DisclosureSEC source: 0001240122-25-000011 · form4-12232025_111200.xml · nonDerivative · entry 2 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted August 22, 2025. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 23:50 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 50,000 | $2.94 | $146,800.00 |
DisclosureSEC source: 0001240122-25-000011 · form4-12232025_111200.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:58 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Disposition to issuerStock Option (Right to Buy) · Derivative | 400 | Not disclosed Strike: $169.50 | Not disclosed |
DisclosureSEC source: 0001240122-25-000009 · form4-12152025_111256.xml · derivative · entry 12 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400 shares Expires 2033-05-24 F1 · derivative.exercise_price: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:58 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 400 | Not disclosed Strike: $104.13 | Not disclosed |
DisclosureSEC source: 0001240122-25-000009 · form4-12152025_111256.xml · derivative · entry 11 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400 Underlying: Common Stock · 400 shares Expires 2033-05-24 F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:58 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Disposition to issuerStock Option (Right to Buy) · Derivative | 666 | Not disclosed Strike: $186.00 | Not disclosed |
DisclosureSEC source: 0001240122-25-000009 · form4-12152025_111256.xml · derivative · entry 10 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 666 shares Expires 2031-12-15 F1 · derivative.exercise_price: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F5 · derivative.exercise_date: 1/48th of the shares vest on a monthly basis from December 16, 2021, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:58 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 666 | Not disclosed Strike: $104.13 | Not disclosed |
DisclosureSEC source: 0001240122-25-000009 · form4-12152025_111256.xml · derivative · entry 9 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 666 Underlying: Common Stock · 666 shares Expires 2031-12-15 F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F5 · derivative.exercise_date: 1/48th of the shares vest on a monthly basis from December 16, 2021, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:58 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Disposition to issuerStock Option (right to buy) · Derivative | 133 | Not disclosed Strike: $1,143.00 | Not disclosed |
DisclosureSEC source: 0001240122-25-000009 · form4-12152025_111256.xml · derivative · entry 8 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 133 shares Expires 2031-05-19 F1 · derivative.exercise_price: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:58 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (right to buy) · Derivative | 133 | Not disclosed Strike: $104.13 | Not disclosed |
DisclosureSEC source: 0001240122-25-000009 · form4-12152025_111256.xml · derivative · entry 7 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133 Underlying: Common Stock · 133 shares Expires 2031-05-19 F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:58 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,499 | Not disclosed Strike: $230.25 | Not disclosed |
DisclosureSEC source: 0001240122-25-000009 · form4-12152025_111256.xml · derivative · entry 6 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,499 shares Expires 2030-08-06 F1 · derivative.exercise_price: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:58 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 1,499 | Not disclosed Strike: $104.13 | Not disclosed |
DisclosureSEC source: 0001240122-25-000009 · form4-12152025_111256.xml · derivative · entry 5 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,499 Underlying: Common Stock · 1,499 shares Expires 2030-08-06 F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:58 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,255 | Not disclosed Strike: $123.00 | Not disclosed |
DisclosureSEC source: 0001240122-25-000009 · form4-12152025_111256.xml · derivative · entry 4 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,255 shares Expires 2030-06-07 F1 · derivative.exercise_price: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:58 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 1,255 | Not disclosed Strike: $104.13 | Not disclosed |
DisclosureSEC source: 0001240122-25-000009 · form4-12152025_111256.xml · derivative · entry 3 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,255 Underlying: Common Stock · 1,255 shares Expires 2030-06-07 F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:58 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Disposition to issuerStock Option (Right to Buy) · Derivative | 387 | Not disclosed Strike: $108.00 | Not disclosed |
DisclosureSEC source: 0001240122-25-000009 · form4-12152025_111256.xml · derivative · entry 2 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 387 shares Expires 2029-07-22 F1 · derivative.exercise_price: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:58 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 387 | Not disclosed Strike: $104.13 | Not disclosed |
DisclosureSEC source: 0001240122-25-000009 · form4-12152025_111256.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 387 Underlying: Common Stock · 387 shares Expires 2029-07-22 F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:04 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001240122-25-000007 · form4-12022025_091224.xml · derivative · entry 5 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 231,176 Underlying: Common Stock · 50,000 shares Expires 2029-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:04 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 50,000 | $74.00 | $3,700,000.00 |
DisclosureSEC source: 0001240122-25-000007 · form4-12022025_091224.xml · nonDerivative · entry 2 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted August 22, 2025. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:04 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 50,000 | $2.94 | $146,800.00 |
DisclosureSEC source: 0001240122-25-000007 · form4-12022025_091224.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 21:10 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001240122-25-000006 · form4-11252025_041104.xml · derivative · entry 5 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 281,176 Underlying: Common Stock · 50,000 shares Expires 2029-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 21:10 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 50,000 | $70.00 | $3,500,000.00 |
DisclosureSEC source: 0001240122-25-000006 · form4-11252025_041104.xml · nonDerivative · entry 2 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted August 22, 2025. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 21:10 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 50,000 | $2.94 | $146,800.00 |
DisclosureSEC source: 0001240122-25-000006 · form4-11252025_041104.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 23:36 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001415889-25-020268 · form4-07242025_110751.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-07-21 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2026 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 23:38 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantDeferred Stock Units · Derivative | 3,977 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015304 · form4-06022025_110615.xml · derivative · entry 2 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,977 Underlying: Common Stock · 3,977 shares Expires not disclosed F2 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. F2 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. F2 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 23:38 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 6,268 | $0.00 Strike: $44.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015304 · form4-06022025_110615.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,268 Underlying: Common Stock · 6,268 shares Expires 2035-05-28 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Read SEC document |
| May 28, 2025 Filed May 30, 2025 20:51 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantStock Option (right to buy) · Derivative | 7,650 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001415889-25-015015 · form4-05302025_080510.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,650 Underlying: Class A Common Stock · 7,650 shares Expires 2035-05-27 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 23:23 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantStock Option (right to buy) · Derivative | 15,300 | $0.00 Strike: $18.20 | $0.00 |
DisclosureSEC source: 0001415889-24-024913 · form4-10082024_111039.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,300 Underlying: Class A Common Stock · 15,300 shares Expires 2034-10-03 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 20:39 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GiftCommon Stock | 102,788 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024195 · form4-10012024_081000.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Grey Family Trust dated November 12,1999 Disclosed balance after: 186,410 F1 · shares: This transaction involved a gift of securities by the reporting person to The Children's Hospital of Philadelphia Foundation. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 22:25 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantDeferred Stock Units · Derivative | 5,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016071 · form4-06072024_100632.xml · derivative · entry 2 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,703 Underlying: Common Stock · 5,703 shares Expires not disclosed F2 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. F2 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. F2 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 22:25 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 8,779 | $0.00 Strike: $26.30 | $0.00 |
DisclosureSEC source: 0001415889-24-016071 · form4-06072024_100632.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,779 Underlying: Common Stock · 8,779 shares Expires 2034-06-04 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. Read SEC document |
| May 22, 2024 Filed May 24, 2024 20:25 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001415889-24-014490 · form4-05242024_080537.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-21 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2025 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| October 06, 2023 Filed Oct 6, 2023 18:19 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Disposition to issuerRestricted Stock Units · Derivative | 4,016 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052373 · doc4.xml · derivative · entry 8 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,016 shares Expires 2024-07-27 F4 · derivative.exercise_price: Each RSU (as defined in footnote 6 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F6 · price: Reflects the disposition of Issuer's restricted stock unit awards (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration. F5 · derivative.exercise_date: The Ordinary Shares subject to the RSUs vest on July 27, 2024. Read SEC document |
| October 06, 2023 Filed Oct 6, 2023 18:19 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Disposition to issuerStock Option (Right to Buy) · Derivative | 32,161 | Not disclosed Strike: $13.87 | Not disclosed |
DisclosureSEC source: 0001209191-23-052373 · doc4.xml · derivative · entry 7 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 32,161 shares Expires 2028-05-02 F3 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2 · derivative.exercise_date: The Option (as defined in footnote 3 to this Form 4) is fully vested. Read SEC document |
| October 06, 2023 Filed Oct 6, 2023 18:19 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Disposition to issuerStock Option (Right to Buy) · Derivative | 31,153 | Not disclosed Strike: $15.12 | Not disclosed |
DisclosureSEC source: 0001209191-23-052373 · doc4.xml · derivative · entry 6 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 31,153 shares Expires 2027-05-02 F3 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2 · derivative.exercise_date: The Option (as defined in footnote 3 to this Form 4) is fully vested. Read SEC document |
| October 06, 2023 Filed Oct 6, 2023 18:19 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Disposition to issuerStock Option (Right to Buy) · Derivative | 23,092 | Not disclosed Strike: $15.23 | Not disclosed |
DisclosureSEC source: 0001209191-23-052373 · doc4.xml · derivative · entry 5 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 23,092 shares Expires 2026-05-02 F3 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2 · derivative.exercise_date: The Option (as defined in footnote 3 to this Form 4) is fully vested. Read SEC document |
| October 06, 2023 Filed Oct 6, 2023 18:19 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,548 | Not disclosed Strike: $28.53 | Not disclosed |
DisclosureSEC source: 0001209191-23-052373 · doc4.xml · derivative · entry 4 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,548 shares Expires 2025-05-05 F3 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2 · derivative.exercise_date: The Option (as defined in footnote 3 to this Form 4) is fully vested. Read SEC document |
| October 06, 2023 Filed Oct 6, 2023 18:19 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Disposition to issuerOrdinary Shares | 10,000 | $116.50 | $1,165,000.00 |
DisclosureSEC source: 0001209191-23-052373 · doc4.xml · nonDerivative · entry 3 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 0 F1 · price: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). Read SEC document |
| October 06, 2023 Filed Oct 6, 2023 18:19 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Disposition to issuerOrdinary Shares | 48,031 | $116.50 | $5,595,611.50 |
DisclosureSEC source: 0001209191-23-052373 · doc4.xml · nonDerivative · entry 2 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Davy Trust Disclosed balance after: 0 F1 · price: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). Read SEC document |
| October 06, 2023 Filed Oct 6, 2023 18:19 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Disposition to issuerOrdinary Shares | 39,361 | $116.50 | $4,585,556.50 |
DisclosureSEC source: 0001209191-23-052373 · doc4.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). Read SEC document |
| September 28, 2023 Filed Sep 28, 2023 16:39 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $15.96 | $0.00 |
DisclosureSEC source: 0001209191-23-050737 · doc4.xml · derivative · entry 4 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 20,000 shares Expires 2024-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| September 28, 2023 Filed Sep 28, 2023 16:39 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 20,000 | $15.96 | $319,200.00 |
DisclosureSEC source: 0001209191-23-050737 · doc4.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 14, 2023 Filed Sep 14, 2023 23:33 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionStock Option (right to buy) · Derivative | 14,216 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001209191-23-049511 · doc4.xml · derivative · entry 8 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 331,176 Underlying: Common Stock · 14,216 shares Expires 2029-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4th of the shares vest one year after November 5, 2018, and the balance of the shares vest in a series of 36 successive equal monthly installments at the end of each month thereafter. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase. Read SEC document |
| September 14, 2023 Filed Sep 14, 2023 23:33 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 14,216 | $32.00 | $454,912.00 |
DisclosureSEC source: 0001209191-23-049511 · doc4.xml · nonDerivative · entry 4 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted August 30, 2022. Read SEC document |
| September 14, 2023 Filed Sep 14, 2023 23:33 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 14,216 | $2.94 | $41,738.18 |
DisclosureSEC source: 0001209191-23-049511 · doc4.xml · nonDerivative · entry 3 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2023 Filed Sep 14, 2023 23:33 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionStock Option (right to buy) · Derivative | 392 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001209191-23-049511 · doc4.xml · derivative · entry 7 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 345,392 Underlying: Common Stock · 392 shares Expires 2029-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4th of the shares vest one year after November 5, 2018, and the balance of the shares vest in a series of 36 successive equal monthly installments at the end of each month thereafter. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase. Read SEC document |
| September 13, 2023 Filed Sep 14, 2023 23:33 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 392 | $32.00 | $12,544.00 |
DisclosureSEC source: 0001209191-23-049511 · doc4.xml · nonDerivative · entry 2 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted August 30, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.